| Followers | 30 |
| Posts | 3419 |
| Boards Moderated | 0 |
| Alias Born | 07/25/2016 |
Wednesday, December 25, 2024 4:10:39 PM
Recent CADL News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 12:58:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 12:17:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:10:26 PM
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/12/2026 12:05:00 PM
- Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston • GlobeNewswire Inc. • 02/24/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:00:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/20/2026 09:16:14 PM
- Candel Therapeutics Announces Pricing of Public Offering • GlobeNewswire Inc. • 02/20/2026 02:40:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/19/2026 09:31:42 PM
- Candel Therapeutics Announces Proposed $100 Million Public Offering • GlobeNewswire Inc. • 02/19/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:03:06 PM
- Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer • GlobeNewswire Inc. • 02/19/2026 09:01:00 PM
- Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:04:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:02:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:01:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:00:12 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 01/21/2026 05:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 01:30:52 PM
- Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 • GlobeNewswire Inc. • 11/17/2025 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 01:30:54 PM
- Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/13/2025 01:25:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
